The lancet oncology
-
The lancet oncology · Feb 2017
A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study.
Despite its common use in cancer treatment, radiotherapy has not yet entered the era of precision medicine, and there have been no approaches to adjust dose based on biological differences between or within tumours. We aimed to assess whether a patient-specific molecular signature of radiation sensitivity could be used to identify the optimum radiotherapy dose. ⋯ None.
-
The lancet oncology · Feb 2017
Randomized Controlled Trial Multicenter Study Comparative StudyPadeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial.
Vascular-targeted photodynamic therapy, a novel tissue-preserving treatment for low-risk prostate cancer, has shown favourable safety and efficacy results in single-arm phase 1 and 2 studies. We compared this treatment with the standard of care, active surveillance, in men with low-risk prostate cancer in a phase 3 trial. ⋯ Steba Biotech.